Market Signal Briefing

-

Will leverage Mitsubishi Electric brand to strengthen global recognition and talent acquisition

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its Thai subsidiary, Siam Compressor Industry Co., Ltd., which develops, manufactures and sells compressors for air conditioning and refrigeration equipment, will change its name to Mitsubishi Electric Siam Compressor Industry Co., Ltd. effective April 1.

In addition to supplying Mitsubishi Electric group companies, Siam Compressor Industry provides a wide range of compressors to other air conditioning equipment manufacturers in Thailand and other countries. In line with the name change, products manufactured and sold by Siam Compressor Industry will adopt the Mitsubishi Electric brand. Through this initiative, the company expects to enhance its global recognition and strengthen its ability to attract talented personnel.

Mitsubishi Electric Siam Compressor Industry will target the growing demand for compressors used in air conditioning and refrigeration equipment in diverse applications, including data centers, a market forecasted to experience significant growth. By expanding its subsidiary’s global business, Mitsubishi Electric expects to accelerate its overall growth in the air conditioning and refrigeration systems business.

For the full text, please visit: www.MitsubishiElectric.com/news/

More News From Mitsubishi Electric Corporation

Back to Newsroom

Analyst’s Disclosure: I/we have a beneficial long position in the shares of XP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of New Era Energy & Digital, Inc. (NASDAQ: NUAI) resulting from allegations that New Era Energy & Digital may have issued materially misleading business information to the investing public.

So What: If you purchased New Era Energy & Digital securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=49293 https://rosenlegal.com/submit-form/?case_id=39889or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On December 12, 2025, Investing.com published an article entitled "New Era Energy & Digital stock falls after Fuzzy Panda short report." The article stated that New Era Energy & Digital stock "tumbled" after "short seller Fuzzy Panda Research released a scathing report targeting the company." Further, the article stated that Fuzzy Panda's short report, "titled 'NUAI: Serial Penny Stock CEO Combined Bad Gas Assets, Paid Stock Promo, Renamed Co & Added 'AI',' alleges that the company spent 2.5 times more on stock promotions than on operating its oil and gas wells. Fuzzy Panda claims CEO E. Will Gray II has a history of running penny stock companies "into the ground" over approximately 20 years."

On this news, New Era Energy & Digital's stock fell 6.9% on December 12, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P.A.

New York, New York--(Newsfile Corp. - February 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PayPal Holdings, Inc. ("PayPal Holdings, Inc.") (NASDAQ: PYPL) concerning potential violations of the federal securities laws.

The timeline of analyst expectations and company communications reveals a notable trajectory. On January 28, 2026, Rothschild & Co Redburn issued a downgrade, cutting PayPal's price target to $50 from $70. The following day, Morgan Stanley also reduced its target to $50, citing slower checkout growth. On February 2, just one day before earnings, analysts published expectations for mid-single-digit revenue growth and higher earnings per share.

The actual results disclosed on February 3 represented a meaningful miss versus these expectations. Revenue of $8.68 billion fell $120 million short of the $8.80 billion estimate, a gap of approximately 1.4%. Adjusted earnings of $1.23 per share missed the consensus range of $1.30 to $1.33 by 5.4% to 7.5%. Perhaps more significantly, the company's forward guidance projected 2026 transaction margin dollars to decline alongside an adjusted earnings per share range of a low single digit decline to a slightly positive gain, figures that were substantially below what the investment community had been modeling.

During the company's third quarter 2025 earnings call on October 28, 2025, approximately 98 days before the latest disclosure, management had not indicated that such a dramatic revision to the company's outlook would be forthcoming. The investigation will examine what information was available to management during this period and when the factors necessitating the lowered guidance became apparent internally.

PayPal shares dropped 19-20% on February 3, falling to approximately $42 and establishing a new 52-week low. Short interest reportedly increased sharply as traders anticipated further declines.

If you suffered a loss on your PayPal Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284012

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - February 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.

What Happened?

On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
According to the Company's release, the FDA acknowledged the results of the previous GRACE and GRADIENT drug trials, but "concluded it could not arrive at a favorable benefit-risk assessment for relacordilant without Corcept providing additional evidence of effectiveness"

Why it Matters:

Today, in direct response to this news, Corcept's stock price fell by $31.42 (44.76%) per share to open at $38.78 per share on December 31, 2025.
This drop marks a new 52-week low for Corcept's stock, dropping to levels not seen since September 2024.

If you suffered a loss on your Corcept Therapeutics Incorporated securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284013

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Property website Rightmove said U.K. house prices in February were virtually flat on month as a high choice of homes for sale and steadying buyer activity prevented a rise.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

– MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –

– Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this –

– Gazyva could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome –

– Gazyva is a glycoengineered, anti-CD20 monoclonal antibody designed to achieve deep tissue B cell depletion –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with Gazyva® (obinutuzumab). Results show that significantly more people achieved complete remission at two years (104 weeks) with Gazyva versus tacrolimus. Safety was in line with the well-characterized profile of Gazyva and no new safety signals were identified.

“These results demonstrate that Gazyva may help more people with primary membranous nephropathy achieve complete remission, maintain kidney function for longer and delay or potentially prevent the onset of life-threatening complications,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “If approved, Gazyva would be the first therapy specifically indicated for people with primary membranous nephropathy, where there are limited treatment options.”

Analysis of key secondary endpoints showed statistically significant and clinically meaningful benefits with Gazyva versus tacrolimus in overall remission (complete or partial remission) at week 104 and complete remission at week 76.

Data will be presented at an upcoming medical meeting and shared with health authorities including the U.S. Food and Drug Administration and the European Medicines Agency.

Primary membranous nephropathy is a chronic autoimmune condition that causes potentially irreversible kidney damage and reduced kidney function, and it is estimated that it affects over 96,000 people in the U.S. Up to 30% of people with primary membranous nephropathy will develop kidney failure over 10 years, which requires invasive intervention like dialysis or transplant and has a significant impact on patients and their families, as well as carrying substantial cost to health systems. Gazyva has the potential to address this by targeting an underlying cause of the condition, which may help maintain kidney function for longer and prevent the onset of life-threatening complications.

MAJESTY is the fourth positive Phase III study of Gazyva in immune-mediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus and INShore in idiopathic nephrotic syndrome. This growing body of evidence supports Gazyva's potential in addressing disease activity across a spectrum of immune-mediated diseases.

Gazyva is approved in the U.S. and European Union for the treatment of adults with active lupus nephritis based on data from the REGENCY and NOBILITY studies and is being investigated in a global Phase II study of children and adolescents with lupus nephritis. Beyond Gazyva, we have a broad pipeline as part of our ambition to be leaders in immunology, in particular in immune-mediated and kidney-related diseases.

About Gazyva
Gazyva® (obinutuzumab) is a humanized monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells. Gazyva is approved for adults with lupus nephritis in the US and EU. Gazyva is also approved in 100 countries for various types of hematological cancers.

About the MAJESTY Study
MAJESTY [NCT04629248] is a Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of Gazyva® (obinutuzumab) in people with primary membranous nephropathy. The study enrolled 142 people who were randomized 1:1 to receive Gazyva or tacrolimus. The primary endpoint is the percentage of people who achieve complete remission at two years (week 104).

About Primary Membranous Nephropathy
Primary membranous nephropathy is a chronic autoimmune condition where the body’s immune system attacks the filtering units of the kidney, the glomeruli, causing protein to leak into the urine and potentially a gradual decline in kidney function. Over time, the damage to the kidneys can become irreversible, increasing the risk of life-threatening complications, such as kidney failure, idiopathic nephrotic syndrome, blood clots and cardiovascular disease. Achieving complete remission is critical to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications.

GAZYVA Indications

GAZYVA® (obinutuzumab) is a prescription medicine used:

With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment With the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment With chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III, or IV FL in adults who have not had previous FL treatment For the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy Important Safety Information

The most important safety information patients should know about GAZYVA

Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that can become serious or life-threatening, including:

Hepatitis B Virus (HBV): Hepatitis B can cause liver failure and death. If the patient has a history of hepatitis B infection, GAZYVA could cause it to return. Patients should not receive GAZYVA if they have active hepatitis B liver disease. The patient’s doctor or healthcare team will need to screen them for hepatitis B before, and monitor the patient for hepatitis during and after, their treatment with GAZYVA. Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin or eyes. Progressive Multifocal Leukoencephalopathy (PML): PML is a rare and serious brain infection caused by a virus. PML can be fatal. The patient’s weakened immune system could put them at risk. The patient’s doctor will watch for symptoms. Symptoms of PML include: confusion, difficulty talking or walking, dizziness or loss of balance, and vision problems. Who should not receive GAZYVA:

Patients should NOT receive GAZYVA if they have had an allergic reaction (e.g., anaphylaxis or serum sickness) to GAZYVA. Patients must tell their healthcare provider if they have had an allergic reaction to obinutuzumab or any other ingredients in GAZYVA in the past.

Additional possible serious side effects of GAZYVA:

Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that may become severe or life-threatening, including:

Infusion-Related Reactions: These side effects may occur during or within 24 hours of any GAZYVA infusion. Some infusion-related reactions can be serious, including, but not limited to, severe allergic reactions (anaphylaxis), acute life-threatening breathing problems, or other life-threatening infusion-related reactions. If the patient has a reaction, the infusion is either slowed or stopped until their symptoms are resolved. Most patients are able to complete infusions and receive medication again. However, if the infusion-related reaction is life-threatening, the infusion of GAZYVA will be permanently stopped. The patient’s healthcare team will take steps to help lessen any side effects the patient may have to the infusion process. The patient may be given medicines to take before each GAZYVA treatment. Symptoms of infusion-related reactions may include: fast heartbeat, tiredness, dizziness, headache, redness of the face, nausea, chills, fever, vomiting, diarrhea, rash, high blood pressure, low blood pressure, difficulty breathing, and chest discomfort. Hypersensitivity Reactions Including Serum Sickness: Some patients receiving GAZYVA may have severe or life-threatening allergic reactions. This reaction may be severe, may happen during or after an infusion, and may affect many areas of the body. If an allergic reaction occurs, the patient’s doctor will stop the infusion and permanently discontinue GAZYVA Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving GAZYVA. GAZYVA works to break down cancer cells quickly. As cancer cells break apart, their contents are released into the blood. These contents may cause damage to organs and the heart and may lead to kidney failure requiring the need for dialysis treatment. The patient’s doctor may prescribe medication to help prevent TLS. The patient’s doctor will also conduct regular blood tests to check for TLS. Symptoms of TLS may include nausea, vomiting, diarrhea, and tiredness. TLS is not identified as a risk in LN. Serious, Including Fatal, Infections: While the patient is taking GAZYVA, they may develop infections. Some of these infections may be fatal and severe, so the patient should be sure to talk to their doctor if they think they have an infection. Patients administered GAZYVA in combination with chemotherapy, followed by GAZYVA alone are at a high risk of infections during and after treatment. Patients with a history of recurring or chronic infections may be at an increased risk of infection. Patients taking GAZYVA plus standard therapy may be at higher risk for fatal or severe infections compared to patients taking standard therapy plus placebo. Patients with an active infection should not be treated with GAZYVA. Patients taking GAZYVA plus bendamustine may be at higher risk for fatal or severe infections compared to patients taking GAZYVA plus CHOP or CVP. If the patient develops a serious infection, your doctor will immediately discontinue GAZYVA and begin treatment for the infection. Low White Blood Cell Count: When the patient has an abnormally low count of infection-fighting white blood cells, it is called neutropenia. While the patient is taking GAZYVA, their doctor will do blood work to check their white blood cell count. Severe and life-threatening neutropenia can develop during or after treatment with GAZYVA. Some cases of neutropenia can last for more than one month. If the patient’s white blood cell count is low, their doctor may prescribe medication to help prevent infections. Low Platelet Count: Platelets help stop bleeding or blood loss. GAZYVA may reduce the number of platelets the patient has in their blood; having low platelet count is called thrombocytopenia. This may affect the clotting process. While the patient is taking GAZYVA, their doctor will do blood work to check their platelet count. Severe and life-threatening thrombocytopenia can develop during treatment with GAZYVA. Fatal bleeding events have occurred in patients treated with GAZYVA. If the patient’s platelet count gets too low, their treatment may be delayed or reduced. Disseminated Intravascular Coagulation (DIC): Fatal and severe DIC has been reported in people receiving GAZYVA. DIC is a rare and serious abnormal blood clotting condition that should be monitored and managed by the patient’s doctor as it can lead to uncontrollable bleeding. The most common side effects of GAZYVA in CLL were infusion-related reactions and low white blood cell counts.

The most common side effects seen with GAZYVA in a study that included relapsed or refractory NHL, including FL patients, were infusion-related reactions, fatigue, low white blood cell counts, cough, upper respiratory tract infection, and joint or muscle pain.

The most common side effects seen with GAZYVA in a study that included previously untreated FL patients were infusion-related reactions, low white blood cell count, upper respiratory tract infections, cough, constipation and diarrhea.

The most common side effects of GAZYVA in LN were upper respiratory tract infection, COVID-19, urinary tract infection, bronchitis, pneumonia, infusion-related reactions, and neutropenia.

Before receiving GAZYVA, patients should talk to their doctor about:

Immunizations: Before receiving GAZYVA therapy, the patient should tell their healthcare provider if they have recently received or are scheduled to receive a vaccine. Patients who are treated with GAZYVA should not receive live vaccines. Pregnancy: The patient should tell their doctor if they are pregnant, think that they might be pregnant, plan to become pregnant, or are breastfeeding. GAZYVA may harm their unborn baby. The patient should speak to their doctor about using GAZYVA while they are pregnant. The patient should talk to their doctor or their child’s doctor about the safety and timing of live virus vaccinations to their infant if they received GAZYVA during pregnancy. Women of childbearing potential should use effective contraception while taking GAZYVA and for 6 months after your GAZYVA treatment. Breastfeeding: Because of the potential risk of serious side reactions in breastfed children, patients should not breastfeed while taking GAZYVA and for 6 months after your last dose. Patients should tell their doctor about any side effects.

These are not all of the possible side effects of GAZYVA. For more information, patients should ask their doctor or pharmacist.

GAZYVA is available by prescription only.

Report side effects to the FDA at (800) FDA-1088, or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.

Please visit https://www.GAZYVA.com for the GAZYVA full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information.

About Genentech in Immunology
Genentech is committed to harnessing pioneering science and innovation to address critical unmet needs for patients with immune-mediated inflammatory diseases. Our pipeline includes over a dozen clinical programs in immunology aiming to transform care for people living with lupus, MASH, ulcerative colitis, Crohn’s disease, immunoglobulin A nephropathy, idiopathic nephrotic syndrome, atopic dermatitis, and rheumatoid arthritis. We are investing end-to-end in immunology from discovery to R&D to commercialization across a variety of modalities including monoclonal antibodies, bispecifics, and CAR-T cell therapies to help solve some of the most difficult challenges in immunology today.

About Genentech
Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rome

Paris, February 16, 2026. A universal respiratory syncytial virus (RSV) immunization program using Beyfortus (nirsevimab) was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study published in The Lancet Infectious Diseases. The NIRSE-GAL study, conducted in Galicia, Spain, is the first prospective real-world population study to evaluate the impact of a universal Beyfortus immunization program during two consecutive RSV seasons. The study findings, comparing the number of hospitalizations in immunized infants during their second RSV season versus the number of expected hospitalization cases based on data from recent seasons, are being presented at RSVVW ’26 (Respiratory Syncytial Virus Vaccines for the Word) conference in Rome, Italy.

The coverage rate was 94.4% among the cohort (11,796 infants out of 12,492 eligible) and the study showed a substantial reduction of 85.9% (95% confidence interval [CI] 80.2–90.0) in RSV-related lower respiratory tract infection (LRTI) hospitalizations during the first season. The study also showed 55.3% (95% CI 22.5-74.3) fewer hospitalizations in the second RSV season among infants who received a dose of Beyfortus during infancy. By preventing severe RSV infections during the first months of life, a critical period of lung development, it is thought the infants may be less prone to subsequent admissions from either RSV or other infections.

"This universal RSV immunization program with Beyfortus showed decreased RSV-related hospitalizations and outpatient illness burden during the first season, with persistent impact seen on RSV hospitalizations through the second season,” said Federico Martinón-Torres, Head of Pediatrics at Santiago University Hospital in Spain, and principal investigator of the NIRSE-GAL study. “These results offer compelling population-based data to inform infant immunization strategies and economic evaluation models.”

"This study builds upon our wealth of evidence supporting the public health value of a Beyfortus immunization program,” said Thomas Triomphe, Executive Vice President, Vaccines, Sanofi. “It’s exciting to see the significant impact of this infant immunization program during the first RSV season and truly remarkable to consider a benefit across two seasons.”

Further findings
The study also showed reductions in primary care consultations during the first RSV season, including:

30.8% (17.5-41.9) reduction in first consultations for acute bronchitis or bronchiolitis; 33.4% (21.6-43.4) reduction in consultations for lower respiratory tract infections and;27.7% (14.9-38.5) reduction in consultations for wheezing or asthma. Furthermore, rehospitalizations in infants previously hospitalized due to RSV decreased considerably during the second RSV season, with a 78.2% (25.6–93.6) reduction in RSV-related rehospitalizations and a 62.4% (30.9–79.6) reduction in LRTI rehospitalizations. These data support the hypothesis that early protection against RSV-related damage to the lungs may have lasting beneficial effects on respiratory health.

About RSV
RSV is a highly contagious virus that can lead to serious respiratory illness for infants. It is a leading cause of hospitalization in all infants, with most hospitalizations for RSV occurring in otherwise healthy infants born at term. Older infants born before the RSV season are also at risk of RSV disease and make up around half of infant RSV hospitalizations. Two out of three infants are infected with RSV during their first year of life and almost all children are infected by their second birthday. Globally, in 2019, there were approximately 33 million cases of RSV-associated acute lower respiratory infections leading to more than three million hospitalizations and an estimated 26,300 in-hospital RSV-attributable deaths of children younger than five years. RSV-related direct medical costs, globally — including hospital, outpatient, and follow-up care — were estimated at c.€5 billion in 2017.

About Beyfortus
Beyfortus (nirsevimab) is the first RSV immunization designed to help protect all infants through their first RSV season, including for those born healthy at term or preterm, and those with health conditions that make them vulnerable to RSV disease. Beyfortus is also approved for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

With an extended half-life of 71 days, Beyfortus is a long-acting monoclonal antibody for the prevention of RSV lower respiratory tract disease in infants.  Administration is timed to coincide with the RSV season and is provided directly to newborns and infants as a single dose. Beyfortus offers rapid protection without requiring activation of the immune system.

Along with efficacy and safety demonstrated in clinical studies, the effectiveness of Beyfortus has been evaluated in more than 50 real-world studies, including more than 400,000 infants who were immunized. Since the launch, over 11 million infants have been immunized with Beyfortus across more than 45 countries.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]
Evan Berland | + 1 215 432 0234 | [email protected]
Léo Le Bourhis | + 33 6 75 06 43 81 | [email protected]
Victor Rouault | + 1 617 356 4751 | [email protected]
Léa Ubaldi | +33 6 30 19 66 46 | [email protected]
Timothy Gilbert | + 1 516 521 2929 | [email protected]
Ekaterina Pesheva | +1 410 926 6780 | [email protected]

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | [email protected]
Alizé Kaisserian | + 33 6 47 04 12 11 | [email protected]
Keita Browne | + 1 781 249 1766 | [email protected]
Nathalie Pham | + 33 7 85 93 30 17 | [email protected]
Nina Goworek | +1 908 569 7086 | [email protected]
Thibaud Châtelet | + 33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]

Sanofi forward-looking statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group. 

Press_Release

LYSAKER, Norway, Feb. 16, 2026 /PRNewswire/ -- The shares in Aker BP ASA (OSE: AKRBP) (OTCQX: AKRBF) will be traded ex dividend USD 0.6615 (NOK 6.29417) per share as from today, 16 February 2026.

The payment date will be on or about 24 February 2026.

Contact:
Kjetil Bakken, Head of Investor Relations, tel.: +47 918 89 889

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/aker-bp-asa/r/aker-bp--ex-dividend-usd-0-6615-today,c4305540

SOURCE Aker BP ASA

The cryptocurrency sector is increasing its political spending ahead of the midterm elections, aiming to replicate the success it achieved during the 2024 federal races. Crypto Industry Gears Up For Midterms Fairshake, a super PAC focused on cryptocurrency policy, announced last month that it had raised $191 million for the 2026 midterm elections.

📊
No votes yet – Be the first to vote

Standard Chartered just cut its crypto forecasts. Hard.

The British banking giant warned investors that Bitcoin could tumble to $50,000 while Ethereum might crash down to $1,400, marking a pretty dramatic shift from their earlier bullish calls. These new numbers came out February 16th after weeks of wild price swings that left even seasoned traders scratching their heads. The bank’s analysts didn’t mince words about what they’re seeing in the markets right now.

Bitcoin’s been all over the place lately. One day it’s up, next day it’s down double digits. Regulatory noise keeps getting louder while economic uncertainty makes everything feel murky. Standard Chartered’s team basically said they can’t ignore what’s happening anymore.

Not exactly shocking news.

The revised Ethereum target of $1,400 shows just how spooked the bank’s gotten about crypto’s wild ride. Their research team spent weeks crunching numbers and watching trading patterns before making the call. A spokesperson told reporters on February 16th that “these changes reflect current market dynamics and are not indicative of the bank’s long-term view.” But that’s exactly what you’d expect them to say, right?

Market watchers saw this coming from miles away. Bitcoin dropped hard from its January highs, dragging pretty much everything else down with it. Ethereum followed the same painful path as investor confidence took a beating. Standard Chartered’s new targets basically mirror what most traders already knew – things got rough fast.

The bank won’t say exactly what might trigger more cuts to their forecasts. Smart move, probably. Related coverage: Bitcoin Hits K Mark as Crypto.

Other big financial players are doing the same thing – cutting targets, getting cautious, watching their backs. It’s like watching dominoes fall in slow motion. Standard Chartered’s analysts keep talking about “external economic pressures” and “macroeconomic factors” but everyone knows what they really mean. Interest rates are moving, inflation’s still a problem, and crypto’s feeling the heat.

February 16th marked a turning point for how Standard Chartered talks about digital assets. Their spokesperson made it clear these forecasts come from “substantial market evidence” rather than gut feelings or hype. The bank’s research team spent considerable time analyzing Bitcoin’s recent price swings, which they blame partly on broader economic headwinds that have historically hammered asset valuations across the board.

Ethereum’s price correction hit different than Bitcoin’s decline. Standard Chartered’s analysts pointed to fluctuating demand and shifting investor sentiment as key drivers behind their decision to slash the target to $1,400. Trading volumes have been all over the map, making it tough to predict where things go next. The bank’s approach involves constant monitoring of these trends, which probably means more forecast changes are coming.

Bitcoin’s drop from its peak earlier this year caught a lot of people off guard. Standard Chartered wasn’t alone in getting blindsided by how fast sentiment shifted. The bank’s updated forecast is basically them admitting they didn’t see the volatility coming this hard or this fast. Their analysts are now watching price movements like hawks, trying to stay ahead of the next big swing.

The ripple effects from these revised targets are already spreading through investor circles. Standard Chartered’s decision follows similar moves by other major financial institutions that have also dialed back their crypto enthusiasm. The bank’s analysts keep emphasizing the need to stay “agile and responsive” to market signals, which sounds like corporate speak for “we have no idea what’s coming next.” Related coverage: Bitcoin price surpasses ,000 again.

A representative from Standard Chartered noted that their forecasts rely on comprehensive data analysis rather than speculation. The spokesperson said these changes show the bank’s commitment to giving clients accurate insights, even when those insights aren’t what people want to hear. Helping investors navigate crypto’s complexities remains a priority, especially when external economic factors keep throwing curveballs at the market.

Standard Chartered’s move isn’t happening in a vacuum – other key financial players are also rethinking their crypto positions. The bank’s proactive stance reflects a broader trend among institutions to adapt quickly when market conditions shift. As volatility continues, Standard Chartered stays focused on delivering data-driven guidance to stakeholders who are probably getting pretty nervous about their crypto holdings.

The bank didn’t provide a timeline for when they might adjust forecasts again. Market participants will have to wait for official communications to learn about any new developments or further target cuts.

The timing of Standard Chartered’s forecast cuts coincides with mounting regulatory pressure from multiple jurisdictions. The European Union’s Markets in Crypto-Assets (MiCA) regulation officially took effect in late 2024, while the U.S. Securities and Exchange Commission continues its enforcement actions against major crypto exchanges. These regulatory developments have created significant uncertainty for institutional investors, with many pulling back from digital asset exposure. JPMorgan Chase and Goldman Sachs have also revised their crypto outlooks downward in recent weeks, citing similar concerns about regulatory clarity and market stability.

Standard Chartered’s $50,000 Bitcoin target represents a 35% decline from current trading levels, putting it in line with forecasts from Barclays and Deutsche Bank. The convergence of these major financial institutions around similar price targets suggests coordinated caution rather than isolated pessimism. Trading data from major exchanges shows institutional volume has dropped by roughly 40% since January, with corporate treasury departments notably absent from recent buying activity. Grayscale’s Bitcoin Trust has seen consistent outflows totaling $2.8 billion over the past month, while MicroStrategy – once crypto’s biggest corporate cheerleader – has remained quiet about additional Bitcoin purchases since their last acquisition in December.

Post Views: 18

Aave is looking beyond traditional crypto lending as it explores a long-term strategy focused on financing solar energy and other real-world infrastructure. 

Summary

Aave founder Stani Kulechov says tokenized solar assets could unlock faster, cheaper funding for clean energy. Aave plans to use solar-backed tokens as collateral to improve liquidity and capital recycling. The move targets long-term growth beyond traditional crypto-based lending. The shift was outlined in a recent post by founder Stani Kulechov, who argued that decentralized finance can play a major role in funding the global energy transition.

Kulechov said on-chain lending has already proven its technical strength with digital assets. The next step, in his view, is to bring productive, real-world assets such as solar farms into DeFi and turn them into usable collateral.

Turning solar projects into liquid assets According to Kulechov, one of the main problems in solar and infrastructure financing is illiquidity. Most projects rely on long-term contracts that can last 20 years or more. Investors often accept lower flexibility in exchange for stable returns, but this also limits the amount of capital that can enter the sector.

Tokenization could change that. By turning solar projects into digital assets, investors would be able to trade and transfer their positions more easily. These tokenized assets could also be used as collateral on Aave (AAVE), allowing developers and financiers to borrow funds quickly instead of waiting months for traditional loans.

Kulechov said this could lower required returns and make projects more attractive. A solar asset that needs a 10% return in private markets might only need 6% if it becomes liquid and tradable. Over time, this could help recycle capital faster, letting the same money fund multiple projects instead of being locked up for decades.

He also pointed to the potential impact on stablecoins. Because solar farms are spread across many countries, their debt could be issued in different currencies. This could create new demand for euro- and pound-backed stablecoins, giving users more options beyond U.S. dollar lending.

Building a new model for DeFi growth Lending against major cryptocurrencies has grown crowded and fiercely competitive, as per Kulechov. Similar products are currently offered by many DeFi platforms, which has decreased long-term growth potential and pushed down margins. 

He argues that solar-backed lending presents an alternative. Aave might fund initiatives that produce actual cash flows and long-term value rather than depending on speculative assets. This would give depositors access to “green yield” while helping fund clean energy development.

He also stressed that most retail investors currently have limited access to solar investments. High minimums and complex structures keep many people out. On-chain products have the potential to reduce these obstacles and increase accessibility to infrastructure financing.

He believes that this strategy reflects a drastic change in the way that capital ought to be distributed. DeFi platforms should support assets that are productive and future-proof rather than concentrating on government debt or struggling industries.

Kulechov described this as an “opinionated” strategy. Users who choose solar-backed products are not just looking for returns, he said. They are choosing to fund creation over extraction and long-term growth over short-term fixes.

If the model works, it might result in a parallel financial system with real infrastructure and revenue supporting lending products and stablecoins. 

“Aave Will Win,” Kulechov concluded, framing the shift as both a business strategy and a statement about the future of DeFI.

In brief Bitcoin’s three-month futures basis has ticked up, suggesting increased derivatives activity. Coinbase CEO says retail users are "buying the dip" with resilient balances Retail typically enters late and suffers most on unwinds, Decrypt was told. Traders are once again cranking up leverage, even as Bitcoin extends its sideways trend and broader crypto market risks persist.

The top crypto has continued to trade between $62,000 and $71,000 since February 6, with no meaningful breakout attempts. Still, investors are piling in, increasing leverage, and hoping for a breakout rally.

“The increase in retail activity signals growing speculation and leverage buildup that frequently comes before volatile crypto movements,” Nick Ruck, Director of LVRG Research, told Decrypt.

The annualized three-month futures basis on major centralized exchanges such as Binance, OKX, and Deribit has widened from approximately 1.5% to 4% since February 13, per Velo data.

The metric measures the gap between the derivatives and spot price. An increased gap suggests futures are trading above spot prices, signalling speculative appetite is returning to the market and traders are increasingly willing to pay a premium for long exposure.

That’s backed by aggregated funding rates rising after February 13, indicating long-position speculators are becoming more dominant. Both metrics reveal a shift that points to a market gradually regaining its risk-on footing after weeks of uncertainty.

“Retail users on Coinbase have been very resilient during these market conditions,” Coinbase CEO Brian Armstrong tweeted Sunday. He added that investors have been “buying the dip” with a “vast majority of customers” seeing their “native unit balances in February equal to or greater than their balances in December.”

Options markets tell a similar story, but hint at a more cautious slant.

The 25 Delta skew—a measure of demand for puts versus calls—has waned steadily since February 13, moving from -10 to -4, according to Deribit data. While the improvement signals reduced demand for downside protection or bearish bets, it could also indicate growing bullish conviction. 

“We expect short-term potential for a leverage-driven rally and short squeezes, especially if broader risk assets hold steady,” Ruck said. 

“Retail typically enters late and suffers the most on unwinds,” the LVRG expert explained, suggesting that “this setup may mark a near-term bottom, but only after the inevitable over-leveraged shakeout occurs.”

Though current market sentiment appears positive, it has yet to be “supported by sufficient trading volume,” according to Ryan Yoon, senior analyst at Seoul-based Tiger Research. 

“This disconnect creates a high-risk environment where any sudden downside could lead to a final, mass surrender of interest,” Yoon told Decrypt. 

With investors at their breaking point, another forced liquidation could extinguish remaining hope entirely, leading to a “total exodus from the market,” the Tiger Research analyst said. “We are at a critical juncture where the line between a healthy recovery and complete investor apathy is becoming dangerously thin.”

Bitcoin is down nearly 2.5% over the past 24 hours, and is trading at $68,600, according to CoinGecko data.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Binance Denies Sanctions Breach Claims After $1 Billion Iran-Linked USDT Transactions Reported Prefer us on Google

Binance denies $1 billion Iran-linked transaction claims.Report alleges dismissed compliance investigators raised concerns.Exchange cites internal review, strengthened sanctions controls.Binance is forcefully rejecting allegations that its internal investigators uncovered more than $1 billion in Iran-linked transactions and were subsequently dismissed.

The pushback escalates tensions between the world’s largest crypto exchange and sections of the financial press.

Sponsored

Sponsored

Binance Rejects Allegations and Defends Compliance RecordThe controversy stems from a February 13 investigative report by Fortune, which alleged that compliance investigators identified over $1 billion in transactions tied to Iranian entities between March 2024 and August 2025.

The transfers reportedly involved Tether (USDT) on the Tron blockchain, an ecosystem frequently scrutinized by regulators for sanctions-related activity.

According to the report, at least five members of Binance’s compliance investigations team were dismissed after raising concerns internally.

Several of the affected staff were described as senior investigators with law enforcement backgrounds. Additional compliance personnel were also said to have departed in recent months, though the precise reasons for their exits were not publicly confirmed.

Binance Says “The Record Must Be Clear”In a public statement, Binance Co-CEO Richard Teng directly refuted the allegations.

“The record must be clear. No sanctions violations were found, no investigators were fired for raising concerns, and Binance continues to meet its regulatory commitments. We’ve asked for corrections to recent reporting,” Teng wrote.

Sponsored

Sponsored

In a formal letter addressed to Fortune, Binance Communications stated that the article contained “gross material inaccuracies and misleading implications.” The company articulated that:

No personnel were terminated for reporting sanctions concerns. No personnel decisions or terminations are related to the reporting of alleged sanctions violations. Binance further asserted that a full internal review, conducted alongside external legal counsel, found no evidence of sanctions breaches related to the referenced activity.

The letter emphasized that the exchange operates under whistleblower protections and strict employment laws across multiple jurisdictions.

Binance also pushed back against suggestions it had reneged on regulatory commitments stemming from its 2023 settlement with US authorities.

Sponsored

Sponsored

The exchange has committed to fully cooperate with monitorship requirements. Reportedly, they have also “significantly strengthened” their sanctions screening, monitoring, and compliance infrastructure since the resolution.

Irresponsible and misleading press articles based on anonymous sources (whether including possibly disgruntled ex-employees or otherwise) does injustice to the great work of our more than 1300 compliance staff working tirelessly to uphold global standards.
Facts:
1. Binance…

— Richard Teng (@_RichardTeng) February 14, 2026 Heightened Sensitivity Post-SettlementThe allegations are particularly sensitive given Binance’s 2023 $4.3 billion settlement over anti-money laundering and sanctions violations. Since then, the exchange has operated under enhanced compliance obligations and increased regulatory scrutiny.

However,beyond the dispute itself, the incident highlights broader concerns about stablecoins and sanctions evasion.

Sponsored

Sponsored

Blockchain analytics firms, including TRM Labs, Chainalysis, and Elliptic, have previously reported growing use of USDT by Iranian-linked actors to move funds outside traditional banking channels.

US authorities, including the Office of Foreign Assets Control (OFAC), have sanctioned other exchanges over similar Iran-linked activity involving USDT on Tron.

🚨 OFAC Sanctions Eight Houthi-Linked Crypto Addresses 🚨

On April 2, 2025, OFAC sanctioned eight crypto addresses tied to a Houthi financing network backed by Iran’s IRGC-QF.

All eight sanctioned addresses are on the Tron network, with most activity in USDT. Elliptic’s… pic.twitter.com/wK1HrynHIF

— Elliptic (@elliptic) April 7, 2025 The standoff remains a battle of narratives, with anonymous-source allegations meeting categorical corporate denials.

With no new enforcement action announced, the question shifts from whether violations occurred to how transparency, compliance, and investigative reporting intersect in an industry still fighting to rebuild trust.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Strategy Inc. (NASDAQ:MSTR) founder Michael Saylor said on Sunday that the Bitcoin (CRYPTO: BTC)-hoarding company plans to convert its convertible debt into equity over the next three to six years. Strategy Won't Issue New Convertible Notes?

Dogecoin corrected some gains and traded below $0.1080 against the US Dollar. DOGE is now holding the $0.10 support but might decline further.

DOGE price started a fresh downside correction from $0.1175. The price is trading above the $0.10 level and the 100-hourly simple moving average. There is a key bullish trend line forming with support at $0.10 on the hourly chart of the DOGE/USD pair (data source from Kraken). The price could aim for a fresh increase if it remains stable above $0.10. Dogecoin Price Dips Again Dogecoin price started a downside correction after it failed to clear $0.1175, unlike Bitcoin and Ethereum. DOGE declined below the $0.1120 and $0.1080 levels.

There was a move below the 50% Fib retracement level of the upward move from the $0.0878 swing low to the $0.1175 high. The bears even pushed the price below $0.1040. However, there is a key bullish trend line forming with support at $0.10 on the hourly chart of the DOGE/USD pair.

Dogecoin price is now trading above the $0.10 level and the 100-hourly simple moving average. Immediate resistance on the upside is near the $0.1035 level. The first major resistance for the bulls could be near the $0.1065 level.

Source: DOGEUSD on TradingView.com The next major resistance is near the $0.1085 level. A close above the $0.1085 resistance might send the price toward $0.1120. Any more gains might send the price toward $0.1150. The next major stop for the bulls might be $0.1175.

More Losses In DOGE? If DOGE’s price fails to climb above the $0.1060 level, it could continue to move down. Initial support on the downside is near the $0.10 level and the trend line.

The next major support is near the $0.0950 level or the 76.4% Fib retracement level of the upward move from the $0.0878 swing low to the $0.1175 high. The main support sits at $0.0928. If there is a downside break below the $0.0928 support, the price could decline further. In the stated case, the price might slide toward the $0.0880 level or even $0.0850 in the near term.

Technical Indicators

Hourly MACD – The MACD for DOGE/USD is now gaining momentum in the bearish zone.

Hourly RSI (Relative Strength Index) – The RSI for DOGE/USD is now below the 50 level.

Major Support Levels – $0.1000 and $0.0950.

Major Resistance Levels – $0.1060 and $0.1085.

Ethereum (ETH) is showing signs of short-term technical weakness as price action on lower time frames forms a micro double top pattern. This bearish formation suggests that ETH may struggle to sustain its recent stabilization attempts following a sharp sell-off that pushed the cryptocurrency from above $3,000 down toward the $2,000 region.

After the steep decline, Ethereum attempted two separate rebounds above the $2,100 resistance level. However, both rallies failed to maintain momentum, resulting in repeated rejections and the creation of a micro double top. In technical analysis, this pattern often signals trend continuation rather than a reversal, especially when it appears after a significant downtrend. The inability of buyers to reclaim key resistance zones highlights weakening bullish strength and leaves ETH vulnerable to renewed selling pressure.

The psychological $2,000 support level is now a critical focal point for traders and investors. Repeated tests of major support typically weaken its reliability over time. A decisive breakdown below $2,000 could trigger increased liquidations and panic selling, potentially driving Ethereum’s price toward the $1,800–$1,700 range, where stronger historical demand has previously emerged.

Technical indicators continue to reflect bearish momentum. Ethereum remains below its major moving averages, which are sloping downward, signaling that sellers remain firmly in control of the broader trend. While short-term relief rallies are possible, they currently appear corrective rather than indicative of a sustainable recovery.

The developing micro double top could also fuel short-term volatility. Failed bounce attempts often trap late buyers, leading to stop-loss cascades and sudden price swings. As a result, traders should prepare for choppy and unpredictable price action as Ethereum navigates this delicate consolidation phase in the crypto market.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

TLDR: Strategy can maintain full debt coverage even if Bitcoin price crashes 88% to $8,000 levels  Michael Saylor plans to convert company’s convertible debt into equity over three to six years  The announcement demonstrates Strategy’s confidence in its balance sheet and risk management approach  Debt-to-equity conversion strategy aligns with Saylor’s long-term bullish outlook on Bitcoin
Strategy announced it can weather a Bitcoin price decline to $8,000 while maintaining sufficient assets to cover all outstanding debt obligations.

The bitcoin-focused company made the statement amid ongoing market volatility. Michael Saylor, the firm’s founder, simultaneously revealed plans to convert convertible debt into equity over a three to six-year period. The disclosure provides insight into the company’s risk management approach.

Financial Buffer Against Market Downturn Strategy’s official statement indicates the company maintains substantial financial cushion despite aggressive bitcoin accumulation.

The company posted that it “can withstand a drawdown in BTC price to $8K and still have sufficient assets to fully cover our debt.” The $8,000 threshold represents an 88% decline from Bitcoin’s current trading levels.

Such a dramatic collapse would bring the cryptocurrency to prices last seen in early 2020. The company’s assertion demonstrates confidence in its balance sheet structure and asset management strategy. Strategy has positioned itself as a corporate bitcoin treasury company.

The firm holds one of the largest corporate bitcoin reserves globally. This financial resilience stems from the company’s debt-to-asset ratio and overall capital structure.

Strategy has raised billions through various financing mechanisms to fund bitcoin purchases. The company apparently structured these obligations with significant downside protection in mind.

Convertible Debt Transformation Timeline Michael Saylor shared his vision for the company’s debt management through a post on X. Saylor stated: “Our plan is to equitize our convertible debt over the next 3–6 years.” This approach would transform debt obligations into equity stakes.

The conversion strategy aligns with Saylor’s long-term bullish outlook on bitcoin. Converting debt to equity reduces fixed obligations and interest expenses. It also provides flexibility as the company continues building its bitcoin position.

The timeline Saylor outlined suggests a gradual transition rather than immediate conversion. This measured approach allows the company to optimize conversion timing based on market conditions.

The strategy potentially reduces dilution risk for existing shareholders while maintaining operational flexibility. The combination of debt coverage capacity and conversion plans reflects Strategy’s evolving corporate structure.

These investments have done well in the past, and the future looks bright.

Who wouldn't want some hyper-growth tech stocks in their portfolio?

Here are some to consider. I'll start off with their performance in recent years, to demonstrate just how hyper-growthy they are, and I'll include returns for a low-fee S&P 500 index fund, too, for comparison. (Note that these S&P 500 returns are a bit outsize, too, as the S&P 500 has averaged annual returns of closer to 10% over many long periods, including years when it declined.)

Equity

5-Year Avg. Annual Return

10-Year Avg. Annual Return

15-Year Avg. Annual Return

Nvidia (NVDA 2.21%)

67.87%

76.81%

47.10%

Palantir Technologies (PLTR +1.71%)

30.22%

N/A

N/A

MercadoLibre (MELI 1.15%)

1.62%

37.26%

25.35%

Vanguard Information Technology ETF (VGT +0.16%)

15.70%

24.24%

18.72%

Vanguard S&P 500 ETF (VOO +0.06%)

13.82%

16.09%

13.77%

Source: Morningstar.com, as of Feb. 9, 2026.

Image source: Getty Images.

1. Nvidia What assortment of hyper-growth stocks wouldn't include semiconductor giant Nvidia? It's been riding the artificial intelligence (AI) wave as it cranks out chips used in data centers for AI processing. Its future looks quite promising, as big tech companies are committing billions of dollars to AI infrastructure.

Today's Change

(

-2.21

%) $

-4.13

Current Price

$

182.81

It also has a new chip coming out, the Rubin, which is designed to facilitate AI inference processes, and it should keep Nvidia competitive. The company's Blackwell chip has already been quite successful and the Rubin platform outperforms it. Clearly, Nvidia is working hard to keep up with advancing technologies.

Better still, Nvidia's stock actually seems appealingly priced, with a recent forward-looking price-to-earnings (P/E) ratio of 24.3, well below the five-year average of 37.4. Wall Street agrees, with the vast majority of analysts rating the stock a buy or strong buy, and one seeing a 90% upside in the stock from recent levels.

2. Palantir Technologies Palantir specializes in AI-based data mining and analytic solutions for businesses and other entities, and counts the U.S. government as a major customer. It's been growing briskly, posting fourth-quarter revenue up 70% year over year and a customer count up 34%.

Today's Change

(

1.71

%) $

2.21

Current Price

$

131.34

Some investors in software companies like to check out the "Rule of 40," which sums a company's annual revenue growth and its adjusted operating margin. Results above 40 are favorable, and Palantir's has gone from 81% in its fourth quarter of last year to a whopping 127% in its recent fourth quarter. Such numbers suggest that Palantir is wringing a lot of profit from every dollar of sales -- and sales are increasing rapidly, too.

Still, everything isn't perfect. Palantir faces great growth potential internationally, but lately it hasn't had the people power to capitalize on that. Some companies might acquire other companies in order to expand their talent base, but Palantir CEO Alex Karp has said that "We don't do acquisitions because we are a thick, dense culture, which means you'd have to fit in."

Palantir's shares have long traded near nosebleed levels, but they're down about 20% year-to-date as I write this, making them somewhat more attractively priced. But with a price-to-sales ratio recently at 80, they're still priced for perfection.

3. MercadoLibre MercadoLibre is a major e-commerce and fintech (financial technology) company serving Latin America. As of its third quarter, it boasted 115 million unique buyers and 72 million monthly active users of its fintech services, with net revenue up 39% year over year and a net profit margin of 5.7%. Management noted that this was "the 27th consecutive quarter of [revenue] growth above 30%."

Today's Change

(

-1.15

%) $

-23.13

Current Price

$

1983.87

The stock has not risen much so far this year, though, partly on concerns about competition, as Sea Limited's Shopee marketplace has been stealing market share from MercadoLibre in Brazil. Two can still win in Latin America, if it comes to that, though, because, per a report from consulting firm Endeavor and MercadoLibre, e-commerce sales in Latin America are likely to grow 1.5 times faster than the global average.

This company has a lot of growth potential, and an attractively priced stock at recent levels, with a forward P/E of 31, well below the five-year average of 64.

4. Vanguard Information Technology ETF Lastly, here's an exchange-traded fund (ETF), a fund that trades like a stock, and one of the best growth ETFs. Its top holdings include several of the "Magnificent Seven" stocks, such as Microsoft, Apple, and Nvidia. It offers an easy way to invest in a lot -- 300-plus -- of growth stocks.

With all of these stocks and this ETF, though, remember that when the market pulls back, as it always does now and then, fast growers can pull back more sharply. Be prepared for volatility, and aim to be a long-term investor, able to ride out downturns.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The article is for informational purposes only (not a solicitation or recommendation to buy or sell stocks). David is not a registered investment adviser. Investors should do their own research or consult a financial adviser to determine what investments are appropriate for their individual situation. This article expresses my opinions, and I cannot guarantee that the information/results will be accurate. Investing in stocks involves risk and could result in losses.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of RWAYI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ADBE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This writing is for educational and informational purposes only. All opinions expressed herein are not investment recommendations and are not meant to be relied upon in investment decisions. The author is not acting in an investment advisor capacity and is not a registered investment advisor. The author recommends investors consult a qualified investment advisor before making any trade. Any projections, market outlooks, or estimates herein are forward-looking statements based upon certain assumptions that should not be construed as indicative of actual events that will occur. This article is not an investment research report but an opinion written at a point in time. The author's opinions expressed herein address only a small cross-section of data related to an investment in securities mentioned. Any analysis presented is based on incomplete information and is limited in scope and accuracy. The information and data in this article are obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed. The author expressly disclaims all liability for errors and omissions in the service and for the use or interpretation by others of information contained herein. Any and all opinions, estimates, and conclusions are based on the author's best judgment at the time of publication and are subject to change without notice. The author undertakes no obligation to correct, update, or revise the information in this document or to otherwise provide any additional materials. Past performance is no guarantee of future returns.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Contact Energy Limited (COENF) Q2 2026 Earnings Call February 15, 2026 5:00 PM EST

Company Participants

Michael Fuge - Chief Executive Officer
Matthew Forbes - Chief Financial Officer
Shelley Hollingsworth - Acting Head of Corporate Finance & Investor Relations and Strategy Manager

Conference Call Participants

Andrew Harvey-Green - Forsyth Barr Group Ltd., Research Division
Vignesh Nair - UBS Investment Bank, Research Division
Grant Swanepoel - Jarden Limited, Research Division
Joshua Dale - Craigs Investment Partners Limited, Research Division
Stephen Hudson - Macquarie Research

Presentation

Michael Fuge
Chief Executive Officer

[Foreign Language] Hello and welcome to Contact's Interim Results presentation for FY '26. We're going to start by reflecting on highlights from the first half and we'll take you through the financial results. We'll then move onto a separate presentation on the $525 million equity raise announced this morning. And then we'll open for question and answers when both presentations have been made. We won't stop at the end of the results section.

Turn to Page 4. First half of FY '26 was transformational for Contact. We completed the Manawa acquisition on the 11th of July 2025, welcoming the Manawa staff and assets to the fold. Integration has since progressed very well and we've secured more than 80% of the announced cost synergies in the first 6 months of ownership, that is on a run rate basis.

Manawa hydro and renewable PPAs increased our renewable generation in the first half by 1.3 terawatt hours. And we generated 0.2 terawatt hours through our new Te Huka 3 geothermal power station. What that meant is that generation was 97% renewable in the first half '26, up from 89% in first half 2025.

EBITDAF was also up 24% to $500 million as a result of the Manawa acquisition and our renewable investments. Profit was up 44% and the Board declared a dividend of $0.16

Hardware and infrastructure stocks have been some of the biggest winners of the AI boom. Is Micron another winner in the making or is it overhyped?

Some of the biggest winners of the artificial intelligence (AI) trend have been the hardware and infrastructure companies supporting it, not the software companies developing AI programs.

Nvidia is probably the best example. AI's demand for its graphics processing units (GPUs) propelled it into the trillion-dollar club a couple of years ago and into becoming the world's most valuable company today with a market cap of $4.6 trillion.

So, it seems one of the best ways to play AI is by investing in the infrastructure supporting it. And one of the most attractive values in the AI infrastructure space right now is Micron Technology (MU 0.56%).

You may have heard about it in connection with memory hardware for AI, but is the Micron opportunity real or is it just hype? Keep reading and I'll tell you.

Image source: Getty Images.

Random Access Memories For your computer to store and access data in the short term, it needs a component called random access memory (RAM). For AI programs to make inferences from data it has been trained on, it needs a lot of RAM or dynamic random access memory (DRAM) a sub-type of memory hardware preferred for AI.

Micron is one of three companies that make up roughly the whole of the memory hardware market. The other two are Samsung and SK Hynix. But the demand AI has put on those three companies has created a shortage in memory hardware.

RAM prices are expected to increase 50% in the first quarter of 2026 alone. Intel CEO Lip-Bu Tan has stated that the memory shortage is unlikely to end until at least 2028.

Micron's business is simple; it designs and produces memory hardware, both RAM and DRAM, for computers. But so great is the opportunity presented by AI's memory needs that Micron actually exited the consumer PC market late last year to focus on AI.

Just last month, Micron, which is based in Boise, Idaho, broke ground on a $100 billion semiconductor factory in upstate New York. The factory is slated to employ over 9,000 people and will be the largest semiconductor factory in the United States once it's completed.

So, Micron is positioning itself to be the dominant provider of memory hardware to the American market.

Today's Change

(

-0.56

%) $

-2.31

Current Price

$

411.66

Memory at a bargain price While Samsung is a larger company than Micron, Micron is the growth opportunity between the two. Micron's revenue for Q1 of its fiscal 2026 (ended Nov. 30, 2025) was up 57% year over year to $13.6 billion. DRAM made up 79% of that number, which shows that most of Micron's growth is coming from AI.

But the revenue wasn't the only highlight. Micron is also incredibly profitable with a gross margin of 56.8%, while its operating margin was 32.5%, and its net margin was 28.15%.

Micron is also trading at an incredible valuation right now. It trades at a forward price-to-earnings (P/E) ratio of 10.57, which is higher than Samsung's 8.5.

However, when we factor in growth for the price-to-earnings-to-growth (PEG) ratio, Micron is at 1.12 to Samsung's 3.31, making it an attractive buy at current prices even after its 330% bull run in the past 12 months.

Believe the hype; Micron is emerging as a serious player in the AI hardware market. So give it a look.